Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06179511 · ClinicalTrials.gov registry record · Phase 1
Study of AZD9829 in CD123+ Hematological Malignancies
A Phase 1 study of Hematological Malignancies, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 20
- Study locations
NCT06179511: Active Phase 1 study of Hematological Malignancies, sponsored by AstraZeneca.
NCT06179511 is a Phase 1 study of Hematological Malignancies that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 56 participants, below the 773-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06179511, a Phase 1 study of Hematological Malignancies, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.
Primary Outcome
DLTs are dose-limiting toxicities as defined in the study protocol.
Conditions Studied
Interventions
- DRUG AZD9829
Study Locations (20)
Other
- Research Site - Heidelberg
- Research Site - Melbourne
- Research Site - Tianjin
- Research Site - Frankfurt
- Research Site - Bologna
- Research Site - Kashiwa
- Research Site - Osaka
- Research Site - Yoshida-gun
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Barcelona
- Research Site - Salamanca
- Research Site - Tainan
California
- Research Site - Duarte
Missouri
- Research Site - St Louis
New York
- Research Site - New York
North Carolina
- Research Site - Chapel Hill
Ohio
- Research Site - Columbus
Texas
- Research Site - Houston
Wisconsin
- Research Site - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2026-03-23 |
| Phase | Phase 1 |
What the registry record for NCT06179511 still lists
NCT06179511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 773-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Hematological Malignancies appearing as the primary indexed condition, and to 1 intervention - of which AZD9829 is the first listed.
NCT06179511 names 20 study sites across 8 states, led by Other, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT06179511 about?
NCT06179511 is a clinical study titled "Study of AZD9829 in CD123+ Hematological Malignancies". This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.
What is the current status of trial NCT06179511?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2024-01-31. Estimated completion is 2026-03-23.
What conditions does trial NCT06179511 study?
This clinical trial studies the following conditions: Hematological Malignancies.
What interventions are being tested in trial NCT06179511?
The interventions under investigation include: AZD9829 (DRUG).
Who is sponsoring clinical trial NCT06179511?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06179511 being conducted?
This trial has 20 study locations across California, Missouri, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06179511's enrollment target sits among peer trials
56 10th of 16 higher than 7 of 16 other Hematological Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematological Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
RECRUITING · Phase 1
-
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Durvalumab and Tremelimumab for Pediatric Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI